Previous Close | 8.69 |
Open | 8.69 |
Bid | 8.69 x 0 |
Ask | 8.70 x 0 |
Day's Range | 8.64 - 8.70 |
52 Week Range | 7.03 - 9.26 |
Volume | |
Avg. Volume | 4,916 |
Market Cap | 101.026M |
Beta (5Y Monthly) | 0.93 |
PE Ratio (TTM) | 16.42 |
EPS (TTM) | 0.53 |
Earnings Date | May 24, 2024 - May 28, 2024 |
Forward Dividend & Yield | 0.18 (2.07%) |
Ex-Dividend Date | Feb 28, 2024 |
1y Target Est | 9.00 |
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include: (CAD)Q4 2023% Change vs. Q4 2022FY 2023% Change vs. FY 2022Canadian Pharma Sales7,989,09810%29,554,89913%International Pharma Sales54,750-54%1,047,74753%Total Company Sales8,273,68611%31,590,30213%EBITDA11,650,3015%7,926,4787%Net Income After Taxes (NIAT)1,450,79121
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth quarter and full year 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exc